{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "other-criteria", "type": "clause", "offset": [66, 80]}, {"key": "approved-by", "type": "definition", "offset": [88, 99]}, {"key": "the-jrc", "type": "clause", "offset": [100, 107]}, {"key": "in-writing", "type": "definition", "offset": [119, 129]}, {"key": "by-the-parties", "type": "clause", "offset": [130, 144]}, {"key": "in-the-course-of", "type": "definition", "offset": [379, 395]}, {"key": "the-research-program", "type": "clause", "offset": [396, 416]}], "snippet": "means (i) those criteria set forth in Exhibit 1.17, and (ii) such other criteria as are approved by the JRC and agreed in writing by the Parties. No criteria shall be deemed Compound Criteria under (ii) unless such criteria are formally approved by the JRC and agreed in writing by the Parties, regardless of whether such criteria are used informally or discussed by the Parties in the course of the Research Program.", "size": 4, "samples": [{"hash": "j3Rev9qlPwJ", "uri": "/contracts/j3Rev9qlPwJ#compound-criteria", "label": "Collaboration and License Agreement (Cytokinetics Inc)", "score": 18.0, "published": true}, {"hash": "ggZefuKppMZ", "uri": "/contracts/ggZefuKppMZ#compound-criteria", "label": "Collaboration and License Agreement (Cytokinetics Inc)", "score": 18.0, "published": true}, {"hash": "5F0mfp6FdDX", "uri": "/contracts/5F0mfp6FdDX#compound-criteria", "label": "Collaboration and License Agreement (Cytokinetics Inc)", "score": 18.0, "published": true}], "hash": "cbffe60f6ca4d6e643c0e8eabbb2feec", "id": 1}, {"snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [6, 18]}, {"key": "collaboration-target", "type": "definition", "offset": [25, 45]}, {"key": "the-jrc", "type": "clause", "offset": [104, 111]}, {"key": "approved-by-the-parties", "type": "definition", "offset": [118, 141]}, {"key": "the-applicable", "type": "clause", "offset": [175, 189]}, {"key": "research-plan", "type": "clause", "offset": [190, 203]}], "snippet": "means the criteria, on a Collaboration Target-by-Collaboration Target basis, that are (i) determined by the JRC, (ii) approved by the Parties, and (iii) documented as part of the applicable Research Plan.", "size": 3, "samples": [{"hash": "j9bbB4YgprD", "uri": "/contracts/j9bbB4YgprD#compound-criteria", "label": "Collaboration and License Agreement (Blueprint Medicines Corp)", "score": 32.5701574264, "published": true}, {"hash": "iPuCiyGXUPl", "uri": "/contracts/iPuCiyGXUPl#compound-criteria", "label": "Collaboration and License Agreement (Blueprint Medicines Corp)", "score": 27.5544147844, "published": true}, {"hash": "5sOuZ2LI4uq", "uri": "/contracts/5sOuZ2LI4uq#compound-criteria", "label": "Collaboration and License Agreement (Blueprint Medicines Corp)", "score": 27.3545516769, "published": true}], "hash": "62496713bed86d739e0d61527d2d7f9e", "id": 2}, {"snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "snippet": "is defined in Section 2.11(b).", "size": 3, "samples": [{"hash": "9xFachPRQ96", "uri": "/contracts/9xFachPRQ96#compound-criteria", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.5174537988, "published": true}, {"hash": "44cYuA4rg53", "uri": "/contracts/44cYuA4rg53#compound-criteria", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.4709103354, "published": true}, {"hash": "5avN2sEBdKN", "uri": "/contracts/5avN2sEBdKN#compound-criteria", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.3175906913, "published": true}], "hash": "7373b3a1b18540bf48c33054a2a698c7", "id": 3}, {"snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [6, 18]}, {"key": "the-development-program", "type": "clause", "offset": [55, 78]}, {"key": "eligibility-for", "type": "clause", "offset": [108, 123]}, {"key": "further-development", "type": "definition", "offset": [124, 143]}], "snippet": "means the criteria set forth in Subsections B and C of the Development Program for determining a Compound\u2019s eligibility for further development.", "size": 2, "samples": [{"hash": "hH8NG6q04cK", "uri": "/contracts/hH8NG6q04cK#compound-criteria", "label": "Asset Purchase Agreement (Ardea Biosciences, Inc./De)", "score": 21.0, "published": true}, {"hash": "7vrbRpNmDMZ", "uri": "/contracts/7vrbRpNmDMZ#compound-criteria", "label": "Master Services Agreement (Ardea Biosciences, Inc./De)", "score": 21.0, "published": true}], "hash": "b2245b36ff83cc3f1a52bc68631c70bc", "id": 4}, {"snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [6, 18]}, {"key": "exhibit-b", "type": "clause", "offset": [29, 38]}], "snippet": "means the criteria listed in Exhibit B for each of [*] Activators, [*] Activators and [*] Activators.", "size": 2, "samples": [{"hash": "8OsEirq2wOb", "uri": "/contracts/8OsEirq2wOb#compound-criteria", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 26.1745379877, "published": true}, {"hash": "iBtyoOgjwyj", "uri": "https://ir.cytokinetics.com/static-files/46c9bdea-b11c-44f2-9b9c-0dc5764f88ec", "label": "ir.cytokinetics.com", "score": 8.6454483231, "published": false}], "hash": "7269c3cdc59cb6815365e1054f19bd35", "id": 5}, {"snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [6, 18]}, {"key": "exhibit-b", "type": "clause", "offset": [29, 38]}], "snippet": "means the criteria listed in Exhibit B for each of [ * ] Activators, [ * ] Activators and [ * ] Activators.", "size": 1, "samples": [{"hash": "cs97dWlqzKi", "uri": "/contracts/cs97dWlqzKi#compound-criteria", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 31.6064339493, "published": true}], "hash": "60726dd3bf5bca3cdb9437082a642c92", "id": 6}, {"snippet_links": [{"key": "by-the-parties", "type": "clause", "offset": [71, 85]}, {"key": "in-writing", "type": "definition", "offset": [86, 96]}, {"key": "for-clarity", "type": "clause", "offset": [98, 109]}, {"key": "the-criteria", "type": "clause", "offset": [119, 131]}, {"key": "other-criteria", "type": "clause", "offset": [162, 176]}, {"key": "by-both-parties", "type": "clause", "offset": [275, 290]}, {"key": "in-the-course-of", "type": "definition", "offset": [387, 403]}, {"key": "preclinical-development-program", "type": "clause", "offset": [408, 439]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [441, 467]}, {"key": "effect-of", "type": "definition", "offset": [536, 545]}, {"key": "change-in-status", "type": "definition", "offset": [600, 616]}, {"key": "agreed-to-by-the", "type": "definition", "offset": [630, 646]}], "snippet": "means (i) those criteria set forth in Exhibit 1.17, as may be modified by the Parties in writing. For clarity, besides the criteria set forth in Exhibit 1.17, no other criteria shall be deemed Compound Criteria unless and until such criteria are formally approved in writing by both Parties, regardless of whether such criteria are used informally or discussed by the JPT or the Parties in the course of the Preclinical Development Program. For the avoidance of doubt, any agreed upon change in the Compound Criteria shall not have the effect of rendering a Compound no longer a Compound unless such change in status is expressly agreed to by the Parties.", "size": 1, "samples": [{"hash": "eiFDiwDuBOE", "uri": "/contracts/eiFDiwDuBOE#compound-criteria", "label": "Co Development and Commercialization Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "hash": "b3880cb1b8a10e722069b963697985b5", "id": 7}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "the-criteria", "type": "clause", "offset": [47, 59]}, {"key": "associated-with", "type": "definition", "offset": [60, 75]}, {"key": "exhibit-d", "type": "definition", "offset": [113, 122]}, {"key": "subject-to", "type": "definition", "offset": [124, 134]}], "snippet": "means, with respect to a given Compound Assay, the criteria associated with such Compound Assay, as set forth on Exhibit D, subject to amendment under Section 3.2(a).", "size": 1, "samples": [{"hash": "gKrfQYPfF6i", "uri": "/contracts/gKrfQYPfF6i#compound-criteria", "label": "License Agreement (Array Biopharma Inc)", "score": 22.8343600274, "published": true}], "hash": "8247146faebd67cf3f555440ab94ee92", "id": 8}, {"snippet_links": [{"key": "the-criteria", "type": "clause", "offset": [6, 18]}, {"key": "exhibit-b", "type": "clause", "offset": [29, 38]}, {"key": "certain-confidential-information", "type": "clause", "offset": [110, 142]}, {"key": "contained-in", "type": "definition", "offset": [143, 155]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [200, 272]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [273, 289]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [303, 334]}, {"key": "as-amended", "type": "definition", "offset": [336, 346]}], "snippet": "means the criteria listed in Exhibit B for each of [*] Activators, [*] Activators and [*] Activators. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to rule 24b-2 of the Securities Exchange Act of 1934, as amended.", "size": 1, "samples": [{"hash": "bf5vawBVhxf", "uri": "/contracts/bf5vawBVhxf#compound-criteria", "label": "License and Collaboration Agreement (Cytokinetics Inc)", "score": 24.5975359343, "published": true}], "hash": "79a51bd1ad914391a9b55076e861a2d1", "id": 9}, {"snippet_links": [{"key": "other-criteria", "type": "clause", "offset": [66, 80]}, {"key": "approved-by", "type": "definition", "offset": [88, 99]}, {"key": "the-jrc", "type": "clause", "offset": [100, 107]}, {"key": "in-writing", "type": "definition", "offset": [119, 129]}, {"key": "by-the-parties", "type": "clause", "offset": [130, 144]}], "snippet": "means (i) those criteria set forth in Exhibit 1.17, and (ii) such other criteria as are approved by the JRC and agreed in writing by the Parties. No criteria shall be deemed Compound Criteria under", "size": 1, "samples": [{"hash": "aWveoF33n15", "uri": "https://ir.cytokinetics.com/static-files/90969ec2-ffc4-4184-98ae-43ab8fc5be84", "label": "Amendment", "score": 12.6440793977, "published": false}], "hash": "48b9eaaea9db90c2ae4d81186702cae0", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIaY29tcG91bmQtY3JpdGVyaWEjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means (i) those criteria set forth in Exhibit 1.17, and (ii) such other criteria as are approved by the JRC and agreed in writing by the Parties. No criteria shall be deemed Compound Criteria under (ii) unless such criteria are formally approved by the JRC and agreed in writing by the Parties, regardless of whether such criteria are used informally or discussed by the Parties in the course of the Research Program.", "size": 20, "title": "Compound Criteria", "id": "compound-criteria", "examples": ["If the JRC agrees that the Collaboration Compound meets the PoC <strong>Compound Criteria</strong>, GSK shall have a right to exercise its PoC Option as to such Collaboration Compound pursuant to Section 4.2.", "If the JRC agrees that the Collaboration Compound meets the Candidate Selection <strong>Compound Criteria</strong>, GSK shall have a right with respect to Project 1 to exercise its Candidate Selection Option as to such Collaboration Compound pursuant to Section 4.2.", "The Steering Committee promptly shall review all such data and other evidence and shall determine whether such Research Compound meets the Recommended <strong>Compound Criteria</strong>.", "A Party may disclose the other Party\u2019s Confidential Information to a Regulatory Authority to the extent such disclosure is required to comply with applicable governmental regulations or to conduct preclinical or clinical studies related to its Collaboration Compounds or Licensed Products, and other compounds that meet the <strong>Compound Criteria</strong> for, and are directed to, its Draft Pick Targets, and related Companion Diagnostics.", "The Parties acknowledge that CK has identified and developed certain Compounds, and that the Compound referred to by CK as [*] may potentially meet the Development <strong>Compound Criteria</strong> guidelines set forth in Exhibit 2.5. In addition, the Parties acknowledge that CK has commenced and is continuing product development activities with respect to [*], and the Parties have discussed CK&#x27;s continuing development program, including the costs thereof, for such Compound.", "The earlier of (i) designation of the first Hit Compound (as defined under the OCA) for such Collaboration Target by the JRC (as defined under the OCA), or (ii) identification of the first Collaboration Compound to meet Hit <strong>Compound Criteria</strong> for such Collaboration Target.* $500,000 2.", "The <strong>Compound Criteria</strong> for each Draft Pick Target will be as narrow as reasonable based on the science available at the time.", "Within the [**] after the Draft Pick Targets and <strong>Compound Criteria</strong> are finalized, Draft Pick Targets will be selected, in writing, by each of the Researching Parties.", "If the Steering Committee determines that such Research Compound meets the Recommended <strong>Compound Criteria</strong>, such Research Compound shall be designated as a Recommended Compound.", "Following such discussions, either Party may make a written request to the other Party to deem such compound as not meeting the <strong>Compound Criteria</strong> for the applicable Draft Pick Target."], "related": [["asam-criteria", "ASAM criteria", "ASAM criteria"], ["lead-compound", "Lead Compound", "Lead Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["selection-criteria", "Selection Criteria", "Selection Criteria"], ["evaluation-criteria", "Evaluation Criteria", "Evaluation Criteria"]], "related_snippets": [], "updated": "2025-07-06T21:58:29+00:00"}, "json": true, "cursor": ""}}